You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
American Association for Clinical Chemistry
Improving healthcare through laboratory medicine
Home
|
Customer Service
|
Site Map
|
Cart
|
Login
About AACC
Members
Events
Government & Public Affairs
Resource Centers
Professional Development
Publications
AACC Store
>
Members
>
NACB - The AACC Academy
>
NACB Blog
Recent Posts
Newborn Screening for Severe Combined Immunodeficiency (SCID): Should it be performed?
Are reference change values more useful than population-based reference intervals?
Autoimmune diabetes and related conditions
Where Is the Hemoglobin S?
Categories
Cancer and Tumor Markers
Case Study
Clinical Translational Science/Proteomics
CVD/Markers/Risk Factors
Diabetes/Endocrinology
Government Affairs/Patient Safety
Immunology/Infectious Disease
Instrumentation/Technology
Management/Medical Informatics
Molecular Pathology and Genetics
New/Other Disease Markers
Nutrition
POC Testing
Renal/GI/Hepatic
Special Populations
TDM/Toxicology
Archives
Year
: 2013
May 2013
April 2013
March 2013
February 2013
January 2013
Year
: 2012
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
Year
: 2011
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
RSS Feed
NACB Blog
Pharmacogenetics: Expectations vs. Reality
2/28/2012 8:28 AM |
Comments (0)
Recommend (871)
By
Linnea M. Baudhuin, PhD, DABMG
Despite the many different clinical applications in the field of pharmacogenetics (PGx), the clinical uptake of pharmacogenetic testing has, for the most part, not yet met expectations. While not all potential PGx applications have robustly proven clinical utility, there are several tests which ha...(
Read More
)
Posted at 2/28/2012 8:28 AM | Tags:
Instrumentation/Technology
|
Molecular Pathology and Genetics
What Specimens Other Than Urine Are Used for the Detection of Drug Abuse?
2/21/2012 8:44 AM |
Comments (1)
Recommend (690)
By
Uttam Garg, PhD, DABCC, DABFT, FACB
Illicit drug abuse remains a significant problem. Drug testing in biological specimens is the most common way to prove and deter drug abuse. Urine is the most widely used matrix for drugs of abuse testing. The advantages of urine specimen include that it is well known specimen, drugs concentra...(
Read More
)
Posted at 2/21/2012 8:44 AM | Tags:
TDM/Toxicology
Will the Use of Dried Filter Paper Specimens (blood, plasma, urine) Become More Common in Clinical Laboratories Other Than for Newborn/Metabolic Screening?
2/14/2012 8:25 AM |
Comments (14)
Recommend (884)
By
Donald H. Chace, PhD, MSFS, FACB
Collection of a few drops of blood on filter paper from the heel of newborns has been the specimen of choice in neonatal screening laboratories for nearly 50 years. Robert Guthrie pioneered the use of this sample collection device for detection of phenylketonuria (PKU). The filter paper, which ...(
Read More
)
Posted at 2/14/2012 8:25 AM | Tags:
Instrumentation/Technology
|
Special Populations
Critical Results: Is Your Lab’s Definition Crisp or Muddled?
2/7/2012 8:51 AM |
Comments (1)
Recommend (919)
By
Gregory J. Buffone, PhD
Since the introduction of critical results reporting by Lundberg over 30 years ago certain issues have remained controversial to this day, at least at our institution, e.g., is it critical or is it simply medically important information? And, if it’s medically important is the laboratory obligate...(
Read More
)
Posted at 2/7/2012 8:51 AM | Tags:
Management/Medical Informatics
|
Government Affairs/Patient Safety
(Hidden) Admin Links
About AACC
|
Members
|
Government & Public Affairs
|
Resource Centers
|
Professional Development
|
Publications
Home
|
Customer Service
|
Site Map
|
AACC Store
|
Login
Contact Us
|
Privacy Policy and Legal Disclaimer
|
Join AACC
©2013 American Association for Clinical Chemistry
1850 K Street, NW Suite 625
Washington, DC 20006
Phone: (800) 892-1400 | Fax: (202) 887-5093